High CD204\(^+\) tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder

Bo Wang\(^{1,2,*}\), Hao Liu\(^{2,*}\), Xiaoliang Dong\(^{1,*}\), Shaoxu Wu\(^2\), Hong Zeng\(^3\), Zhuowei Liu\(^4\), Di Wan\(^2\), Wen Dong\(^2\), Wang He\(^2\), Xu Chen\(^2\), Limin Zheng\(^5\), Jian Huang\(^2\), Tianxin Lin\(^{1,2}\)

1. Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, PR China
2. Department of Urology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen (Zhongshan) University, Guangzhou, PR China
3. Department of Pathology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen (Zhongshan) University, Guangzhou, PR China
4. Department of Urology, Cancer Center, Sun Yat-Sen (Zhongshan) University, Guangzhou, PR China
5. State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen (Zhongshan) University, Guangzhou, PR China

*These authors have contributed equally to this work

Correspondence to:
Tianxin Lin, e-mail: tianxinl@sina.com
Jian Huang, e-mail: urolhj@sina.com

Keywords: tumor-infiltrating macrophages, CD204, CD169, urothelial cell carcinoma of the bladder (UCB)

Received: December 03, 2014   Accepted: April 25, 2015   Published: May 07, 2015

ABSTRACT

Macrophages (Mφs) are a major cell type that can infiltrate solid tumors and exhibit distinct phenotypes in different tumor microenvironments. This study attempted to investigate the prognostic values of various tumor-infiltrating Mφ phenotypes in patients with urothelial cell carcinoma of the bladder (UCB), with a focus on Mφ tissue microlocalization. Mφs were assessed by immunohistochemistry in tissues from 302 UCB patients using CD68 as a pan-Mφ marker, and CD204 and CD169 as robust pro- and anti-tumoral Mφ phenotype markers, respectively. Our data showed that these Mφ phenotypes were predominately distributed in stromal (ST) rather than in intratumoral (INT) regions (all \(P < 0.0001\)). Surprisingly, CD204 and CD169 can be co-expressed by the same CD68\(^+\) Mφs. Kaplan-Meier analysis revealed that all INT- and ST-infiltrating CD204\(^+\) or CD169\(^+\) Mφ densities were inversely associated with overall survival (all \(P < 0.01\)). By multivariate analysis, ST-infiltrating CD204\(^+\) Mφ density emerged as an independent prognostic factor for overall survival (HR, 1.981; \(P = 0.022\)). Moreover, the density of ST-infiltrating CD204\(^+\) Mφs was positively associated with the tumor size (\(P = 0.001\)), tumor stage (\(P < 0.0001\)), nodal metastasis (\(P < 0.0001\)), and histological grade (\(P < 0.0001\)). Our findings suggest that CD204\(^+\) Mφs might play detrimental protumoral roles and represent the predominant Mφ phenotype in human bladder cancer.

INTRODUCTION

Bladder cancer is the most common type of urological tumor and more than 90% of patients present as urothelial cell carcinoma of the bladder (UCB) [1–2]. The intravesical instillation of bacillus Calmette–Guerin has been used as an effective immunotherapeutic strategy to prevent recurrence and progression in selected patients with non-muscle-invasive bladder cancer [2–4], suggesting that UCB is a potentially immunogenic type of tumor. Tumor progression has been recognized to be the product of crosstalk that evolves between different cell types within tumors [5–6]. Tumor-infiltrating macrophages (Mφs) have been shown to have both pro- and anti-tumorigenic functions, which could be a consequence of the different tumor microenvironments that promote their differentiation into distinct subpopulations [7–8]. In mice, diverse Mφ subpopulations can be distinguished based on the expression of several specific markers [9]. However, many markers that have been used to identify murine Mφs

www.impactjournals.com/oncotarget
cannot be translated to differentiate human Mφs [7, 9]. CD68, a pan-Mφ marker, is widely used to evaluate Mφ density in diverse types of human tumors; however, the expression of CD68 does not allow for discrimination between diverse Mφ phenotypes, which can be associated with different patient prognosis [10–13]. In breast cancer, CD68+ Mφs can be categorized into two subgroups based on thymidine phosphorylase (TP) that are associated with strikingly different prognosis: a TP+ Mφ group that shows a poor prognosis and a TP− Mφ group that shows a good prognosis [12]. In renal cell carcinoma, combined analysis of CD11c+ Mφs and CD206+ Mφs can more accurately predict patient outcomes compared to analysis of CD68+ Mφs alone [13]. Therefore, a more detailed characterization of distinct Mφ subpopulations might provide an opportunity to eliminate protumoral Mφs or harness antitumoral Mφs in human cancers.

CD204, also known as scavenger receptor A, is a phagocytic pattern-recognition receptor that is primarily expressed on myeloid lineage cells and is involved in homeostatic functions, such as lipid metabolism and phagocytosis [14]. Emerging evidence has shown that the tumor microenvironment can cause the upregulation of CD204 expression on Mφs. Furthermore, a high density of tumor-infiltrating CD204+ Mφs is associated with worse patient outcomes in various types of cancer [15–17]. Additionally, CD169, a member of the sialic-acid-binding immunoglobulin-like lectin family, is expressed on myeloid lineage cells, notably on subpopulations of tissue resident Mφs and inflammatory Mφs in mice and humans [18–19]. A recent study showed that CD169+ Mφs dominate antitumor immunity by cross-presenting tumor antigens to CD8+ T cells [20]. Taken together, these observations suggest that CD204 and CD169 could serve as Mφ subpopulation markers and that they might aid the design of novel anti-tumor vaccines. To date, very little is known about the density, localization, and clinical relevance of CD204+ Mφs and CD169+ Mφs in human bladder cancer.

Herein, we investigated the distribution and prognostic significance of CD68+ Mφs, CD204+ Mφs, and CD169+ Mφs in 302 UCB patients. For all of these Mφ phenotypes, a trend for localization in stromal (ST) rather than in intratumoral (INT) regions of UCB tissues, as well as a higher frequency of ST-infiltrating CD204+ Mφs, could predict a poor prognosis, independent of other tumor-infiltrating Mφ phenotypic markers and clinical variables. Our data suggest that CD204+ Mφs can play protumoral roles that are detrimental and could represent the predominant Mφ phenotype in human bladder cancer.

RESULTS

Immunohistochemical characteristics

Mφs exhibit diverse phenotypes during inflammation and tumor pathogenesis [21–22]. To evaluate Mφ phenotypes and distribution patterns in human UCB tissues, we used immunostaining to study CD68+ Mφs, CD204+ Mφs, and CD169+ Mφs in situ. Clear and distinguishable staining was evident for both CD68 and each Mφ phenotype marker (Fig. 1). Using two-color immunofluorescence analyses, we also observed that CD204+ Mφs and CD169+ Mφs could be observed among the CD68+ Mφs (Supplementary Fig. 1).

Previous studies showed that Mφs could be detected in different locations within and around a tumor [7, 11]. We also found that CD68+ Mφs were distributed throughout the tissues, and were more frequent in ST than in INT regions of UCB tissues (35 ± 26 and 15 ± 14 cells/field, respectively; Fig. 1; n = 302). Moreover, the frequencies of both CD204+ Mφs and CD169+ Mφs were significantly higher in ST regions (24 ± 36 and 31 ± 20 cells/field, respectively) than in the corresponding INT regions of UCB tissues (13 ± 16 and 4 ± 9 cells/field, respectively). These findings indicated that CD204+ Mφs and CD169+ Mφs show the same localization bias as CD68+ Mφs in UCB tissues (both P < 0.0001; Fig. 1C).

To analyze potential associations between cell densities for CD68+ Mφs, CD204+ Mφs, and CD169+ Mφs, Spearman’s rank correlation coefficients were calculated (Supplementary Table 1). The densities of all three markers were positively associated with each other in INT and associated ST regions, except for the association between CD204+ Mφs and CD169+ Mφs (P = 0.066). Using triple color immunofluorescence analyses, we also observed that CD204 and CD169 can be co-expressed on the same Mφs in both INT and ST regions of UCB tissues (Fig. 2).

Survival analysis

To investigate the association of diverse Mφ phenotypes with UCB progression, we divided 302 UCB patients into two groups based on the median frequencies of CD68+ Mφs, CD204+ Mφs, and CD169+ Mφs, respectively. Kaplan–Meier survival curves were then plotted to further investigate associations with survival (Fig. 3). The log-rank statistic was used to compare survival rates. We did not detect any association between OS and CD68+ Mφ density (P = 0.19, Fig. 3A), but we found a marked negative association between OS and the densities of CD68+ Mφs (P < 0.0003, Fig. 3B), CD204+ Mφs (P = 0.0008, Fig. 3E), CD204+ Mφs (P = 0.0003 Fig. 3F), CD169+ Mφs (P = 0.005, Fig. 3I), and CD169+ Mφs (P < 0.0001, Fig. 3J). However, the presence of these cells did not show any prognostic significance for RFS (all P > 0.05, Fig. 3C-3D, 3G-3H, 3K-3L, Supplementary Table 2). After dichotomization at the median cell density for the pan-Mφ marker and Mφ markers for each activation phenotype, the 5-year OS rate was 71% above the median compared to 90% below the median for CD68+ Mφs, 74% vs. 87% for
Figure 1: CD68⁺ Mφs, CD204⁺ Mφs, and CD169⁺ Mφs were enriched in the stromal regions of UCB tissues (n = 302). A. Anti-α-SMA staining was used to distinguish intratumoral (INT) from stromal (ST) regions. B. Representative immunohistochemistry images of CD68⁺ Mφs, CD204⁺ Mφs, and CD169⁺ Mφs in human UCB tissues. The micrographs at higher magnification show stained INT (1) and ST (2) regions. Scale bar, 100 μm. C. The numbers of CD68⁺ Mφs, CD204⁺ Mφs, and CD169⁺ Mφs in the INT and ST regions of human UCB tissues. Cell numbers were calculated as the cell count per ×400 field. Data are expressed as means ± SEM.
CD204+ INT Mφs, 70% vs. 91% for CD204+ ST Mφs, 68% vs. 85% for CD169+ INT Mφs and 71% vs. 89% for CD169+ ST Mφs. When the clinicopathological variables that were significant in the univariate analysis were adopted as covariates (Table 1), multivariate analysis revealed that the density of CD204+ ST Mφs was an independent prognostic factor for OS (HR, 1.981; \( P = 0.022 \)).

To further evaluate the prognostic value of CD204+ ST Mφs in different UCB patient subgroups, patients were stratified according to age (Fig. 4A-4B), tumor size (Fig. 4C-4D), tumor stage (Fig. 4E-4F), and histological grade (Fig. 4G-4H). The density of CD204+ ST Mφs maintained its prognostic value in predicting a shorter OS in all of these subgroups, except for OS in patients who had a tumor size greater than 3 cm (\( P = 0.29 \)). Therefore, CD204+ ST Mφs could represent a powerful prognostic factor for patients with UCB in different risk groups.

The association of CD204+ ST macrophage density and clinicopathological variables

The correlation between CD204+ ST Mφ density and clinicopathological variables was further evaluated by \( \chi^2 \) analysis (Table 2). The density of CD204+ ST Mφs was positively associated with tumor size (\( P = 0.001 \)), tumor stage (\( P < 0.0001 \)), nodal metastasis (\( P < 0.0001 \)), and histological grade (\( P < 0.0001 \)). These findings indicate that large tumors, high TNM stage, and poorly differentiated UCB are risk factors that favor the infiltration of CD204+ Mφs in the ST of UCB tissues.

DISCUSSION

Mφs are versatile, plastic cells that can respond to microenvironmental signals and display a broad spectrum of different phenotypes in human tumors [10, 21–22]. Therefore, we investigated the distribution of Mφ phenotypes in different microlocalizations within tumors and assessed their prognostic significance in UCB patients. We found that CD204 and CD169 are primarily expressed on CD68+ Mφs, and that they can be co-expressed on the same Mφs. All CD68+ Mφs, CD204+ Mφs, and CD169+ Mφs were found to be distributed throughout the tissue, but were often more prominent in ST than in INT regions in UCB tissues. Moreover, a high density of CD204+ ST Mφs could predict a poor prognosis for UCB patients and can be positively associated with tumor size, tumor stage, nodal metastasis, and histological grade. These data provide new insights into the significance of the location, density, and functional orientation of different immune cell populations in human tumor progression.

Previous studies have always used CD68 as a single immunohistochemical pan-Mφ marker to evaluate the location and density of Mφs and their clinical relevance in bladder cancer, but the results have been conflicting [23–24]. In a study of 63 patients with bladder cancer, Nomura et al. reported that patients exhibiting a high tumor-infiltrating Mφ density had worse postsurgical outcomes compared to those patients with a low tumor-infiltrating Mφ density [23]. However, in another study that used tissue microarrays to analyze 296 bladder cancer tissues, Hoglund et al. observed that tumor-infiltrating CD68+ Mφ density showed no association with patient survival [24]. These discrepancies are probably a consequence of differences in the number, stage, and size of tumors. Moreover, none of these studies evaluated the distribution of Mφ phenotypes within different microlocalizations.

Human tumor tissues can be anatomically classified into INT and ST regions, and each has distinct compositional and functional properties [25–26]. Therefore, we focused on the tissue microlocalization...
Figure 3: Cumulative overall survival and recurrence-free survival curves are shown for patients with UCB (n = 302). Kaplan–Meier survival estimates and log-rank tests were used to analyze the prognostic significance of CD68+ Mφs, CD204+ Mφs, and CD169+ Mφs in intratumoral (INT) and stromal (ST) regions. Patients were divided into two groups according to the median number of these Mφs per ×400 field. A, C, CD68+ Mφs in INT regions (CD68+ INT Mφs, median = 12); B, D, CD68+ Mφs in ST regions (CD68+ ST Mφs, median = 27); E, G, CD204+ Mφs in INT regions (CD204+ INT Mφs, median = 6); F, H, CD204+ Mφs in ST regions (CD204+ ST Mφs, median = 12); I, K, CD169+ Mφs in INT regions (CD169+ INT Mφs, median = 0); and J, L, CD169+ Mφs in ST regions (CD169+ ST Mφs, median = 30.5). Black lines, low group; red lines, high group.

Figure 4: The accumulation of CD204+ Mφs in stromal regions predicts a poor prognosis in different subgroups of UCB patients. Kaplan–Meier survival estimates and log-rank tests were used to analyze the prognostic significance of ST-infiltrating CD204+ Mφs (CD204+ ST Mφs) in each subgroup. All patients were stratified according to age A-B, tumor size C-D, tumor stage E-F, and histological grade G-H.
of CD68⁺ Mφs, CD204⁺ Mφs, and CD169⁺ Mφs in 302 patients with UCB. Our data showed that INT-infiltrating CD68⁺ Mφ density showed no association with patient survival, but ST-infiltrating CD68⁺ Mφ density was negatively associated with patient survival. In contrast to the conflicting prognostic significance of CD68⁻ Mφs (pan-Mφs), both high INT- and ST-infiltrating CD204⁺ Mφ densities were found to be adverse signs in patients with UCB. Moreover, ST-infiltrating CD204⁺ Mφ density emerged as an independent predictor of prognosis and maintained its prognostic value to predict shorter survival with different risk groups in UCB patients. In accordance with our results, previous studies showed that a high density of tumor-infiltrating CD204⁺ Mφs is associated with worse prognosis in renal, lung, and pancreatic cancers [15–17]. These findings suggest that CD204⁺ Mφs could represent a stable and reliable prognostic indicator for UCB.

CD204 is cell-surface glycoprotein that belongs to the scavenger receptors with a protumoral function during...
tumor progression [14, 27]. Studies of mouse models showed that the expression of CD204 helped dormant tumor cells to acquire invasiveness capability, and that loss of CD204 affected tumor metastasis at the initial inoculation site [27]. Consistent with these observations, our study showed that CD204⁺ Mφs in ST regions were positively associated with tumor stage, nodal metastasis, and histological grade. Moreover, we observed that CD204 did not co-localize with immunosuppressive molecules, such as IL-10, B7-H1, or B7-H4, in UCB tissues (data not shown), which suggested that the expression of CD204 on Mφs is sufficient to promote tumor progression independently of other pathways.

CD169 is a macrophage-restricted cell surface receptor with a profound regulatory effect on T cell tumoricidal responses, which suggested that CD169⁺ Mφs are antitumorigenic [19–20]. Using a hepatocellular carcinoma model system, the antitumoral role of CD169⁺ Mφs could be further supported by the finding that CD169⁺ Mφs exhibited an activated phenotype and promoted Th1/Tc1 cell responses via CD169-medicated Mφ–T cell interactions (unpublished observations). Surprisingly, we found that CD169⁺ Mφ density was associated with shorter OS in UCB, although it was not an independent predictor in multivariate analysis. As CD169 can be co-expressed with CD204 on the same Mφs, a possible explanation for the detrimental effect of Mφs on patient prognoses is that Mφ with protumoral phenotypes (e.g., CD204) might be more prevalent than those with antitumoral phenotypes (e.g. CD169) in UCB tissues. Testing this hypothesis may be the subject of further investigations.

### Table 2: Associations between CD204⁺⁺ Mφ density and the clinicopathological characteristics of UCB

| Variable                  | Low       | High      | R   | P    |
|---------------------------|-----------|-----------|-----|------|
| No. of patients           | 151 (50%) | 151 (50%) |     |      |
| Age, years                |           |           | 0.086 | 0.135 |
| ≤60                       | 85 (28%)  | 72 (24%)  |     |      |
| >60                       | 66 (22%)  | 79 (26%)  |     |      |
| Gender                    |           |           | 0.039 | 0.499 |
| Male                      | 133 (44%) | 129 (43%) |     |      |
| Female                    | 18 (6%)   | 22 (7%)   |     |      |
| Tumor size                |           |           | 0.183 | <0.0001 |
| ≤3 cm                     | 129 (43%) | 106 (35%) |     |      |
| >3 cm                     | 22 (7%)   | 45 (15%)  |     |      |
| Multifocality             |           |           | 0    | 1    |
| Unifocal                  | 107 (35%) | 107 (35%) |     |      |
| Multifocal                | 44 (15%)  | 44 (15%)  |     |      |
| Tumor stage               |           |           | 0.333 | <0.0001 |
| Ta–T1                     | 129 (43%) | 83 (27%)  |     |      |
| T2–T4                     | 22 (7%)   | 68 (23%)  |     |      |
| Nodal metastasis          |           |           | 0.207 | <0.0001 |
| N0                        | 150 (50%) | 136 (45%) |     |      |
| N1–N2                     | 1 (0%)    | 15 (5%)   |     |      |
| Histological grade        |           |           | 0.315 | <0.0001 |
| Low                       | 111 (37%) | 64 (21%)  |     |      |
| High                      | 40 (13%)  | 87 (29%)  |     |      |

**Abbreviations:** UCB, urothelial cell carcinoma of the bladder; CD204⁺⁺ Mφ, CD204⁺ Mφ in stromal regions. Significant P-values are shown in bold font.
The identification of pro- and anti-tumoral Mφ phenotypes has largely been accomplished using in vitro or mouse models, while less evidence has been reported for their differential expression in human tissues in situ [28–29]. Our findings indicated that a potent protumoral Mφ phenotype marker, CD204, and a potent antitumoral Mφ phenotype marker, CD169, can be co-expressed on the same Mφs in human UCB tissues. Moreover, the number of ST-infiltrating CD204-expressing Mφs was positively correlated with disease progression and could potentially be used as a prognostic marker for UCB patients, despite the simultaneous presence of CD169-expressing Mφs.

MATERIALS AND METHODS

Patients and tissue specimens

Tissue specimens were obtained from January 2003 to December 2009 from 302 patients who had pathologically confirmed UCB at the Cancer Center of Sun Yat-sen University. No patient had a distant metastasis or received anticancer therapies prior to surgery, and none of them were treated with BCG immunotherapy after surgery. All tumors were graded according to the World Health Organization 2004 classification and staged according to the TNM classification (6th edition, 2002). Patient clinicopathological characteristics are summarized in Table 3. All samples were anonymously coded in accordance with the local ethical guidelines (as stipulated by the Declaration of Helsinki). Written informed consent was obtained from all patients and the protocol was approved by the Review Board of the Cancer Center.

Patient follow-up data were obtained by the Cancer Center Tumor Registry, as described previously [30–32]. Briefly, patients were prospectively evaluated every 3 months during the first year, every 6 months during the second year, and annually thereafter. Follow-up visits consisted of a history, physical examination, and routine biochemical analyses. Ultrasonography of the abdomen, urography, and chest X-rays were performed at 3, 6, and 12 months postoperatively, and then annually unless otherwise clinically indicated. Abdominal/pelvic CT scans were performed 6 months postoperatively and annually thereafter. Bone scans were performed when clinically indicated. All tumor recurrences were histologically confirmed. Moreover, the survival status of all patients was updated by telephone contact in November 2014. The median follow-up for living patients was 82 months (range, 4–137 months). Overall survival (OS) was defined as the interval between surgery and death or between surgery and the last observation for surviving patients. Recurrence-free survival (RFS) was defined as the interval between surgery and recurrence or between surgery and the last observation for patients without recurrence. Among the 302 patients who were examined, 76 (25.2%) died, 100 (33.1%) had tumor recurrences, and 153 (51.7%) remained alive without recurrence during the follow-up period.

Immunohistochemistry

Formalin-fixed and paraffin-embedded samples were cut into 5-μm sections, which were then processed for immunohistochemistry as previously described [32]. Briefly, 5-μm thick paraffin sections were first deparaffinized and hydrated, then endogenous peroxidase activity was blocked by incubating the slides in 0.3% H2O2. Antigen retrieval was performed by microwave treatment in citrate buffer (pH 6.0). Sections were blocked with normal sera from the same species from which secondary antibodies were derived. After overnight

| Table 3: Clinicopathological characteristics of urothelial cell carcinoma of the bladder patients |
|-----------------------------|-----------------------------|
| Variable                   | No.                         |
| No. of patients            | 302                         |
| Age, years (median, range) | 60 (15–90)                  |
| Gender (male/female)       | 262/40 (86.8%/13.2%)        |
| Tumor size (≤3 cm/>3 cm)   | 235/67 (77.8%/23.2%)        |
| Multifocality (unifocal/multifocal) | 214/88 (70.9%/29.1%) |
| Tumor stage (Ta–T1/T2–T4)  | 212/90 (70.2%/29.8%)        |
| Nodal metastasis (N0/N1–N2) | 286/16 (94.7%/5.3%)         |
| Histological grade (low/high) | 175/127 (57.9%/42.1%)      |
| Follow-up, months (median, range) | 82 (4–137)                  |
incubation at 4°C with antibodies against human α-SMA (1:500 dilution, Zhongshan Bio-Tech Co., Zhongshan, China), CD68 (1:500 dilution, Dako A/S, Glostrup, Copenhagen, Denmark), CD169 (1:200 dilution, R&D Systems, Minneapolis, MN, USA), CD204 (1:500, dilution, Transgenic, Kumamoto, Japan), or control antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), sections were incubated with secondary antibodies conjugated to horseradish peroxidase (Envision + Dual Link Kit, DAKO, for mouse/rabbit antibodies; or R&D Systems for donkey anti-sheep secondary antibody) for 30 min. The enzymatic reactions were developed using a peroxidase-labeled secondary antibody followed by 3,3′-diaminobenzidine tetrahydrochloride using the Envision System (Dako). Sections were counterstained with hematoxylin (Zymed Laboratories, San Francisco, CA, USA) and mounted in nonaqueous mounting medium.

**Immunofluorescence**

For immunofluorescence staining, paraffin-embedded tissue sections were first incubated with rabbit anti-human CD68 and mouse anti-human CD204, or/sheep anti-human CD169, followed by incubation with specimen-paired immunofluorescence secondary antibodies (Life Technologies). Isotype-matched primary antibodies were used as negative controls. Images were captured and analyzed on a Zeiss LSM710 system using ZEN software (Zeiss, Oberkochen, Germany).

**Evaluation of immunohistology**

Tissue sections were analyzed by two independent observers who were blinded to the clinical outcome. The localization patterns of infiltrating cells in the tumors were divided into two different regions, defined as the intratumoral (INT) and stromal (ST) regions. Anti-α-SMA antibody was used to facilitate the identification of tumor ST regions, as described previously [24]. To evaluate the density of tissue-infiltrating CD68⁺ Mφs, CD169⁺ Mφs, and CD204⁺ Mφs, tissue sections were screened at a low-power field (100×) and the five most representative fields were selected for analysis at 400× magnification (0.07 mm² per field) using a Nikon DS-Fi2 CCD camera (Nikon, Tokyo, Japan) that was installed on a Nikon Eclipse 80i microscope (Nikon, Tokyo, Japan). The infiltrating cells per field were enumerated manually and counts were expressed as means ± SEM. A significant linear correlation existed between the counts of two independent observers and the average count of the two investigators was used in subsequent analyses to minimize inter-observer variability.

**Statistical analyses**

Statistical analyses were performed using SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). The statistical significance of differences between groups was determined using the Wilcoxon signed-rank test. Cumulative survival time was calculated using the Kaplan–Meier method and was analyzed by the log-rank test. A multivariate Cox proportional hazards model was used to estimate the adjusted hazard ratios and 95% confidence intervals (CIs), and to identify independent prognostic factors. For categorical analyses, the median value was used as a cut-off to dichotomize continuous variables (for clinical applications). Associations between variables were analyzed using Spearman ρ coefficient tests and relationships between categorical variables were analyzed using χ² tests. For such comparisons, two-tailed P-values < 0.05 were considered to indicate statistically significant differences.

**ACKNOWLEDGMENTS**

This study was funded by grants from China Postdoctoral Science Foundation (Grant No. 2014M562241), the National Natural Science Foundation of China (Grant Nos. 81402106, U1301221, 81472384, 81372729, 81372883, 81272808, 81172431, 81101935), Guangdong Province Natural Scientific Foundation (Grant No. S2013020012671, 07117336, 10151008901000024), the Specialized Research Fund for the Doctoral Program of Higher Education (for Tianxin Lin, 20130171110073), the Sun Yat-Sen University Clinical Research 5010 Program (Grant No. 2007018), the Elite Young Scholars Program of Sun Yat-Sen Memorial Hospital (for Tianxin Lin, J201401), the National Clinical Key Specialty Construction Project for Department of Urology, Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun-Yat-Sen University and Grant [2013] 163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology.

**CONFLICTS OF INTEREST**

No potential conflicts of interest were disclosed.

**REFERENCES**

1. Jacobs BL, Lee CT, Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin. 2010; 60:244–272.
2. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, Sylvester R, Kaasinen E, Bohle A, Palou Redorta J, Roupret M. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013; 64:639–653.
3. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol. 2014; 11:153–162.

4. Bevers RF, Kurth KH, Schamhart DH. Role of urothelial cells in BCG immunotherapy for superficial bladder cancer. Br J Cancer. 2004; 91:607–612.

5. Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004; 4:839–849.

6. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21:309–322.

7. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerd S, Gordon S, Hamilton JA, Ivashik LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Naloli G, et al. Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. Immunity. 2014; 41:14–20.

8. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4:71–78.

9. Qian BZ, Pollard JW. Macrophage diversity enhances tumour progression and metastasis. Cell. 2010; 141:39–51.

10. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013; 229:176–185.

11. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66:605–612.

12. Laoui D, Movahedi K, Van Overmeire E, Van den Bossche J,Schoupp E, Mommer C, Nikolau A, Morias Y, De Baetselier P, Van Ginderachter JA. Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol. 2011; 55:861–867.

13. Xu L, Zhu Y, Chen L, An H, Zhang W, Wang G, Lin Z, Xu J. Prognostic value of diametrically polarized tumor-associated macrophages in renal cell carcinoma. Ann Surg Oncol. 2014; 21:3142–3150.

14. Bowdish DM, Gordon S. Conserved domains of the class A scavenger receptors: evolution and function. Immunol Rev. 2009; 227:19–31.

15. Komohara Y, Hasita H, Ohnishi K, Fujiwara Y, Suzu S, Eto M, Takeya M. Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci. 2011; 102:1424–1431.

16. Kaku Y, Imaoka H, Morimatsu Y, Komohara Y, Ohnishi K, Oda H, Takenaka S, Matsuoka M, Kawayama T, Takeya M, Hoshino T. Overexpression of CD163, CD204 and CD206 on alveolar macrophages in the lungs of patients with severe chronic obstructive pulmonary disease. PLoS One. 2014; 9:e87400.

17. Sugimoto M, Mitsunaga S, Yoshikawa K, Kato Y, Gotohda N, Takahashi S, Konishi M, Ikeda M, Kojima M, Ochiai A, Kaneko H. Prognostic impact of M2 macrophages at neural invasion in patients with invasive ductal carcinoma of the pancreas. Eur J Cancer. 2014; 50:1900–1908.

18. O’Neill AS, van den Berg TK, Mullen GE. Sialoadhesin -a macrophage-restricted marker of immunoregulation and inflammation. Immunology. 2013; 138:198–207.

19. Klaas M, Crocker PR. Sialoadhesin in recognition of self and non-self. Semin Immunopathol. 2012; 34:353–364.

20. Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, Kanagawa O, Fujii S, Tanaka M. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity. 2011; 34:85–95.

21. Balkwill FR, Capasso M, Hagemann T. The tumor micro-environment at a glance. J Cell Sci. 2012; 125:5591–5596.

22. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13.

23. Hanada T, Nakagawa M, Emoto A, Nomura T, Nasu N, Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol. 2000; 7:263–269.

24. Sjodahl G, Lovgren K, Lauss M, Chebil G, Patschan O, Gudjonsson S, Mansson W, Ferno M, Leandersson K, Lindgren D, Liedberg F, Hoglund M. Infiltration of CD3 and CD68 cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urol Oncol. 2014; 32:791–797.

25. Wu Y, Zheng L. Dynamic education of macrophages in different areas of human tumors. Cancer Microenviron. 2012; 5:195–201.

26. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313:1960–1964.

27. Neyen C, Pluddemann A, Mukhopadhyay S, Maniati E, Bossard M, Gordon S, Hagemann T. Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer. J Immunol. 2013; 190:3798–3805.

28. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009; 206:1327–1337.

29. Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009; 33:118–126.

30. Huang J, Lin T, Liu H, Xu K, Zhang C, Jiang C, Huang H, Yao Y, Guo Z, Xie W. Laparoscopic radical
cystectomy with orthotopic ileal neobladder for bladder cancer: oncologic results of 171 cases with a median 3-year follow-up. Eur Urol. 2010; 58:442–449.

31. Liu J, Cai M, Chen J, Liao Y, Mai S, Li Y, Huang X, Liu Y, Zhang J, Kung H, Zeng Y, Zhou F, Xie D. alpha4 contributes to bladder urothelial carcinoma cell invasion and/or metastasis via regulation of E-cadherin and is a predictor of outcome in bladder urothelial carcinoma patients. Eur J Cancer. 2014; 50:840–851.

32. Wang B, Shaoxu W, Zeng H, Liu Z, Dong W, Wang H, Chen X, Dong X, Zheng L, Lin T, Huang J. CD103 tumor-infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol. 2015; pii: S0022-5347:03268-1.